Published in Vaccine on October 17, 2006
Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5. J Virol (2009) 1.69
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther (2010) 1.27
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
Smallpox vaccines: targets of protective immunity. Immunol Rev (2011) 1.21
The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination. J Exp Med (2008) 1.19
Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol (2007) 1.19
Vaccinia virus exhibits cell-type-dependent entry characteristics. Virology (2009) 1.09
Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol (2010) 1.04
Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge. J Virol (2008) 1.01
Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol (2008) 1.01
Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology (2007) 1.00
Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology (2007) 1.00
Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans. Virology (2009) 0.99
A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine (2010) 0.98
Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine (2009) 0.96
Smallpox vaccines for biodefense. Vaccine (2009) 0.92
Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS One (2011) 0.92
Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin. Clin Vaccine Immunol (2010) 0.91
The structure of the poxvirus A33 protein reveals a dimer of unique C-type lectin-like domains. J Virol (2009) 0.90
Smallpox subunit vaccine produced in Planta confers protection in mice. Proc Natl Acad Sci U S A (2007) 0.90
Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. J Virol (2014) 0.89
Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol J (2009) 0.87
Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. J Virol (2007) 0.86
The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. Vaccine (2009) 0.85
Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. J Virol (2013) 0.84
Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein. J Virol (2010) 0.83
Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. Virol J (2011) 0.83
Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine (2010) 0.80
New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens. Virology (2009) 0.80
Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines. Clin Vaccine Immunol (2007) 0.79
Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology (2011) 0.78
Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model. Clin Vaccine Immunol (2010) 0.78
Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox. Sci Rep (2015) 0.77
The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry. J Virol (2012) 0.77
Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge. Vaccine (2012) 0.76
TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines. PLoS One (2014) 0.76
Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens. PLoS One (2011) 0.76
The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy. J Virol (2013) 0.75
Defending against smallpox: a focus on vaccines. Expert Rev Vaccines (2016) 0.75
Containing bioterrorist smallpox. Science (2002) 7.62
Duration of antiviral immunity after smallpox vaccination. Nat Med (2003) 7.39
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
A model for a smallpox-vaccination policy. N Engl J Med (2002) 3.79
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A (2004) 3.08
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol (1985) 3.06
A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology (1995) 2.82
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol (2004) 2.72
Poxvirus entry and membrane fusion. Virology (2006) 2.69
A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology (1992) 2.67
Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope. J Virol (1992) 2.60
Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis (2003) 2.46
Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein. Virology (1990) 2.27
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol (2005) 2.18
DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology (2000) 2.16
Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology (1999) 2.15
Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide. Gene (1991) 2.13
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol (2005) 2.11
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology (2003) 2.07
Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene. J Virol (1996) 2.03
Ectromelia virus: the causative agent of mousepox. J Gen Virol (2005) 1.99
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98
CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine (2000) 1.80
The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine (2005) 1.74
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS (2005) 1.68
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Smallpox: setting the research agenda. Science (1999) 1.43
LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J Virol (2006) 1.38
Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology (2005) 1.32
Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol (2002) 1.26
Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine (2000) 1.25
The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies. Proc Natl Acad Sci U S A (2005) 1.24
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine (2004) 1.23
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 1.19
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 1.15
Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine (2004) 1.12
Identification of a vaccinia virus penetration protein. Virology (1994) 1.11
Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine (2006) 1.08
CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol (2003) 0.94
Biodefense. Smallpox vaccines: looking beyond the next generation. Science (2004) 0.91
Crystal structure of glycoprotein B from herpes simplex virus 1. Science (2006) 5.57
Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med (2009) 4.22
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity (2003) 3.49
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Structure of unliganded HSV gD reveals a mechanism for receptor-mediated activation of virus entry. EMBO J (2005) 2.95
Respiratory dendritic cell subsets differ in their capacity to support the induction of virus-specific cytotoxic CD8+ T cell responses. PLoS One (2009) 2.70
Activation, differentiation, and migration of naive virus-specific CD8+ T cells during pulmonary influenza virus infection. J Immunol (2004) 2.50
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 2.48
Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol (2010) 2.45
Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. Proc Natl Acad Sci U S A (2007) 2.43
Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med (2010) 2.22
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol (2005) 2.13
Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nat Med (2002) 2.12
Low levels of SIV infection in sooty mangabey central memory CD⁴⁺ T cells are associated with limited CCR5 expression. Nat Med (2011) 2.08
Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol (2005) 2.07
Preferential migration of effector CD8+ T cells into the interstitium of the normal lung. J Clin Invest (2005) 2.07
Herpes virus fusion and entry: a story with many characters. Viruses (2012) 2.05
Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods (2007) 2.04
Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM). J Virol (2002) 2.03
Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother (2004) 2.02
Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression. Immunity (2005) 1.99
Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry. J Virol (2003) 1.92
Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB. J Virol (2010) 1.91
The soluble ectodomain of herpes simplex virus gD contains a membrane-proximal pro-fusion domain and suffices to mediate virus entry. Proc Natl Acad Sci U S A (2004) 1.89
Differential response of respiratory dendritic cell subsets to influenza virus infection. J Virol (2008) 1.85
Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol (2005) 1.85
Mutational evidence of internal fusion loops in herpes simplex virus glycoprotein B. J Virol (2007) 1.79
Structure-based mutagenesis of herpes simplex virus glycoprotein D defines three critical regions at the gD-HveA/HVEM binding interface. J Virol (2003) 1.78
CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol (2011) 1.75
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology (2007) 1.73
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. J Virol (2010) 1.70
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS (2005) 1.68
Herpes simplex virus glycoprotein B associates with target membranes via its fusion loops. J Virol (2009) 1.65
Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J Exp Med (2010) 1.61
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. J Virol (2007) 1.56
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem (2002) 1.53
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog (2011) 1.53
The envelope G3L protein is essential for entry of vaccinia virus into host cells. J Virol (2006) 1.49
Physical and immunological characterization of a recombinant secreted form of the membrane protein encoded by the vaccinia virus L1R gene. Virology (2005) 1.49
Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis (2006) 1.46
Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R. J Virol (2005) 1.44
Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci U S A (2006) 1.44
Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem (2002) 1.43
In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol (2004) 1.39
Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J Virol (2005) 1.39